A transfection assay in a lymphoblastoid cell line infected with Epstein-Barr virus 2 was used to compare the ability of type 1 and type 2 EBNA2 to sustain cell 3 proliferation. The reduced proliferation in cells expressing type 2 EBNA2 correlated 4 with loss of expression of some cell genes that are known to be targets of type 1 5 EBNA2. Microarray analysis of EBNA2 target genes identified a small number of 6 genes that are more strongly induced by type 1 than type 2 EBNA2 and one of these 7 genes (CXCR7) was shown to be required for proliferation of lymphoblastoid cell 8 lines. The Epstein-Barr virus LMP1 gene was also more strongly induced by type 1 9 EBNA2 than type 2 but this effect was transient. Type 1 and type 2 EBNA2 were 10
Gene Expression Analysis V5.0.1, Agilent Technologies). Data extraction was 1 performed with feature extraction software V9.1.3.1 by using the protocol file "GE2-2 v5_91_0806.xml". AK31:EBNA1/ER-EBNA2 type 1 or type 2 cells were pre-treated 3 for 1hr with protein synthesis inhibitors, then with or without estrogen for 4 hrs in the 4 presence of protein synthesis inhibitors. Total cell RNA was extracted and used for 5 expression profiling. The experiment was performed in duplicate and the resulting 6
RNAs were hybridised pairwise (estrogen-treated versus control) on four individual 7 microarrays. The geometric mean of the four ratios/probe across all arrays was 8 calculated. The output files from the Agilent Feature Extraction software for each 9 microarray include the signal (MedianSignal), standard deviation of the signal 10 (PixSDev), background (BGMedianSignal) and corrected signal (ProcessedSignal; dye-11 normalized signal after surrogate algorithm, used for computation of log ratio) for each 12 channel (Cy3 and Cy5). From these, a signal to noise (S/N) ratio for each channel (= 13 signal/background) and relative error (= SD signal/signal) were calculated. Analyses 14 were done with the log ratio calculated from the corrected signals (Cy3 and Cy5). To 15 describe the quality of the ratio value the smaller of the two S/N values was used while 16 for the relative error the higher one was selected. The microarray data analysis was 17 performed using the software Genedata Expressionist® Pro (Genedata AG, Basel, 18
Switzerland). 19
Immunoblotting and ELISA 20 SDS gel electrophoresis and Western immunoblotting was performed as described 21 previously (38). Antibodies and dilutions used were EBNA2, DAKO PE2 mouse 22 monoclonal (1/500); LMP1, DAKO CS1-4 mouse monoclonal (1/500); IRF4, AB-23 ELISA for IL-1β used the Quantikine DLB50 kit (R&D systems). AK31:EBNA1/ER-5 EBNA2 T1 or T2 cells were treated with estrogen for 24 hours or kept untreated as 6 controls and then protein was extracted in 200 μl CAT-ELISA buffer. The extract was 7 added to the ELISA plate provided in the kit and incubated for 2 hours. The plate was 8 washed 3 times then incubated for 1hr with secondary antibody, washed three times 9 and developed, following the instructions with the kit. 10
11

Analysis of DNA content by Propidium Iodide staining 12
Cell were harvested and fixed in 70% ethanol in PBS overnight at 4 °C. Fixed cells 13 were washed three times in 1ml cold PBS, then resuspended in 500 μl 50μg/ml 14 propidium iodide (PI) in PBS containing RNaseA (0.5mg/ml) and incubated for 30 15 minutes at 37 °C prior to analysis. PI-stained cells were then analysed for DNA 16 content by flow cytometry. 17
18
Apoptosis assays 19
For the JC-1 assay, cells were cultured at a density of 1 x 10 6 cells/ml in medium 20 containing 2 μM JC-1 (Molecular Probes, Invitrogen) for 30 minutes at 37 °C, 5% 21 CO 2 . Positive control samples were also incubated with 50 μM membrane potential 22 disrupter CCCP (Molecular Probes, Invitrogen) to uncouple mitochondria. After the 23 incubation period, cells were washed in 2 ml warm PBS and resuspended in 500 μl 24 PBS for analysis by flow cytometry.
1
To measure DNA laddering, cells were harvested after treatment and DNA was 2 extracted as described (15). The extent of DNA fragmentation was visualised on a 1% 3 agarose gel containing Ethidium Bromide. 4
5
Results 6
Assay for EBNA2 function distinguishes type 1 from type 2 7
Transfection of an oriP plasmid expressing wild-type type 1 EBNA2 into EREB2.5 8 cells was previously demonstrated to allow continued growth of the cells in the 9 absence of estrogen. EBNA2 is known to be essential for the growth of LCLs and the 10 wild type EBNA2 takes over from the ER-EBNA2, the episomal ER-EBNA2 plasmid 11 eventually being lost from the cells (16, 24, 37 H thymidine declined and cell proliferation ceased (Fig 1A) . A 20 negative control transfection in which a plasmid expressing no EBNA2 was 21 transfected gave no significant 3 H thymidine incorporation. Such transfections 22 eventually resulted in outgrowth in the absence of estrogen of typical LCLs with type 23 1 EBNA2 (Fig 1B) . These cells expressed EBNA2 and after 3 months in culture had 24 almost completely lost expression of the ER-EBNA2 fusion protein, as detected by 25 western blotting (Fig 1B) , presumably because of passive loss of the ER-EBNA2 1 plasmid from the cells. The plasmids encoding type 1 and type 2 differed only in the 2 EBNA2 coding region and expressed similar levels of EBNA2 protein at early times 3 after transfection (3 days), as detected by Western blotting with the PE2 monoclonal 4 antibody ( Fig 1C) . To check that the PE2 monoclonal antibody detects type 1 and 5 type 2 EBNA2 with equal efficiency on a western blot, EBNA2 was prepared by in 6 vitro translation incorporating 35 S methionine. Dilutions of the samples were analysed 7 by western blotting with PE2 and a phosphorimager was used to measure 35 
S Met 8
incorporation on the same gel. The results ( Fig 1D) showed that PE2 detected type 1 9
and type 2 EBNA2 with approximately equal efficiency in the western blotting assay. 10
11
In Figure 1A , the key point of difference in the time course of 3 H thymidine 12 incorporation was about 3 to 4 days after transfection, when incorporation in the type 13 1 transfection was still increasing strongly as the cells proliferated but the culture with 14 type 2 EBNA2 was stopping DNA synthesis. EBNA2 regulates expression of the viral 15 LMP1 protein and LMP1 signal transduction is an important factor in proliferation 16 and survival of EBV LCLs but it was noticeable that the level of LMP1 3 or 4 days 17 after transfection and estrogen withdrawal was similar in the western blotting samples 18 from the type 1 and type 2 transfections. In contrast, there were major differences in 19 the expression level of some cell genes identified previously as EBNA2 targets, for 20 example RUNX3 and IRF4 ( Fig 1C) . We showed previously that RUNX3 is required 21 for proliferation of EREB2.5 LCLs (38) so this experiment indicates that differential 22 expression of a cell gene that is directly controlled by EBNA2 correlates with the 23 different proliferative capacity of type 1 and type 2 EBNA2. 24
25
Identification of cell genes differentially regulated by type 1 and type 2 EBNA2 1 Our previous strategy for identification of direct target genes of type 1 EBNA2 in the 2 EREB2.5 LCL background (37) can not be applied to type 2 EBNA2 because the ER-3 EBNA2 (type 2) does not sustain cell proliferation. There were many similarities in 4 the lists of EBNA2 target genes identified by our approach and that of EBNA2 5 expression in an EBV negative Burkitt's lymphoma cell line (28) so we therefore 6 created EBV negative Akata (AK31) BL cell lines with constitutive expression of 7 type 1 or type 2 ER-EBNA2. The ER-EBNA2 was expressed from episomal oriP 8 vectors selected with G418 and the EBNA1 required for this plasmid maintenance 9 was provided from another oriP plasmid in the cells under puromycin selection. 10
There was characteristically some stabilisation of the EBNA2 protein when the cells 11 were treated with estrogen (Fig 2) , as is seen also in EREB2. (also known as RDC1, CMKOR1). The induction of mRNA expression for these 24 genes was about 3 fold higher with type 1 EBNA2. 25 1 Induction of IL1β was confirmed at the protein level in AK31:EBNA1/ER-EBNA2 2 (type 1) cells in response to estrogen activation of the EBNA2, both by ELISA assay 3 (Fig 3A) and Western blotting (Fig 3B) , but this protein was intracellular and could 4 not be detected in the culture medium. RT-PCR for ADAMDEC1 confirmed its 5 induction ( Fig 3C) and MARCKS has been reported previously to be induced by EBV 6 infection of BL cells (6) . Interestingly, CXCR7 was the RNA most strongly induced 7 by EBNA2 type 1 in our previous study on direct EBNA2 targets in EREB2.5 LCLs 8 (37) and was also found to be strongly induced in the EBV negative BL cell 9 background in other studies (28). 10 11 Induction of CXCR7 was confirmed by RT-PCR both in the AK31:EBNA1/ER-12 EBNA2 T1 cells and in EREB2.5 cells in response to estrogen activation of the 13 EBNA2 (Fig 4A) . Two known splice variants in the leader exons of CXCR7 and a 14 novel splice of exon 2 directly to the coding exon were observed in the RT-PCR 15 assays (Fig 4A) . The differential regulation of CXCR7 and ADAMDEC1 by type 1 16 and type 2 EBNA2 observed in the BL cell lines (Fig 2) was also seen in EREB2.5 17 cells transfected with EBNA2 expression vectors followed by withdrawal of estrogen 18 (Fig 4B) , similar to the experiment shown in Fig 1. The time course of the experiment 19
in Fig 4B was slightly slower than that shown in Fig 1 and the differential regulation  20 of CXCR7 and ADAMDEC1 by type 1 and type 2 EBNA2 was most clearly seen 7 21 and 10 days after transfection, relative to a GAPDH control (Fig 4B) . EREB2.5 cells 22
were not unusual in expressing CXCR7; a similar pattern of expression was observed 23 in a panel of LCLs (Fig 4C) . These LCLs were derived from cord blood (C2-BL16, 24 C2-Akata, IB4, EREB2.5) or peripheral blood (LCL3, Obaji LCL) B cells and 25 contained several different EBV strains (LCL3 contains B95-8 EBV). C2-BL16 1 contains a type 2 EBV but has a similar level of CXCR7 RNA to the other lines, 2 suggesting that once an LCL has been established, cells with this level of CXCR7 3 may be selected, if CXCR7 is required for LCL proliferation or survival. 4 5 Using a similar shRNA plasmid transfection approach to that we applied previously to 6 test the contribution of RUNX3 and p55α PI3kinase to LCLs (37, 38), we 7 investigated the effect of depleting CXCR7. Knockdown of CXCR7, detected at the 8 RNA level (Fig 5A, B) , resulted in a severe impairment of accumulation of 9 transfected EREB2.5 cells (Fig 5A) or LCL3 cells (Fig 5B) and cell death. In those 10 experiments p53 RNAi and the empty vector were used as negative controls (37, 38) 11 and affected neither the levels of CXCR7 RNA nor accumulation of the cells in 12 culture. The shRNA plasmids were also transfected into 293 cells and puromycin 13 selection was applied (Fig 5C) . There was no difference between the CXCR7 and 14 empty vector shRNA plasmids in the production of puromycin resistant 293 cells, 15
indicating that the CXCR7 shRNA construct was not non-specifically toxic and did 16 not prevent function of the puromycin resistance gene used in Fig 5A, In the experiment shown in Fig 2C, 2 EBV so we therefore compared the effects of type 1 and type 2 ER-EBNA2 on 10 AK31 BL cells over a longer time period. Both type 1 and type 2 ER-EBNA2 11 suppressed c-MYC protein levels (Fig 6A) and caused the previously described (21) 12 accumulation of cells in the G1 phase of the cell cycle after about 24 hours (Fig 6B) . 13
In addition to the previously reported cell cycle arrest (21), these BL cells 14 subsequently died by apoptosis in response to EBNA2 expression. The accumulation 15 of cleaved PARP (Fig 6B) , sub-diploid DNA content on FACS (Fig 6B) , JC-1 assay 16 (Fig 6C) and DNA laddering (Fig 6D) all confirmed the apoptotic mechanism of cell 17 death. Similar effects of accumulation in G1 and subsequent apoptosis were also 18 observed in DG75 EBV negative BL cells containing the same ER-EBNA2 plasmids 19 (data not shown) Both type 1 and type 2 EBNA2 caused all these effects but in some 20 experiments the PARP cleavage in response to type 2 EBNA2 was slightly slower 21 (Fig 6A) . 22 1 Differential regulation of LMP1 by type 1 and type 2 EBNA2 2 A previous report compared the levels of LMP1 in LCLs stably expressing type 1 or 3 type 2 EBNA2 and found them to be similar (9) . We transfected the ER-EBNA2 4 (type 1 and type 2) plasmids into Daudi BL cells, which contain an endogenous EBV 5 genome with a deletion of the EBNA2 gene, and selected transfected cell lines with 6 G418. Because LMP1 is normally induced by EBNA2, LMP1 protein is not usually 7 present in Daudi cells at a significant level. When EBNA2 function was induced by 8 adding estrogen, type 1 EBNA2 induced LMP1 much more rapidly than type 2 9 EBNA2 (Fig 7) , even though the expression of type 2 EBNA2 was slightly stronger 10 (Fig 7) . This difference in LMP1 induction was large but transient; after 48 hours 11 there was little difference in the levels of LMP1, consistent with the previously 12 published result in cells stably expressing type 1 or type 2 EBNA2 (9) . In contrast to 13 the EREB2.5 cells (Fig 1) , where the continued expression of LMP1 was measured EBNA-LP that is expressed from p554 series plasmids (24). There is some evidence 18 that type 1 and type 2 EBNA-LP can differ in their ability to cooperate with EBNA2 19 (29) in induction of the LMP1 promoter and that EBV sequence variation in the 20 LMP1 promoter (studied in P3HR1 EBV) can cause it to respond to type 1 EBNA2 21 slightly differently from the prototypic B95-8 LMP1 promoter (18). In some respects 22 it is surprising that we observed no outgrowth with type 2 EBNA2 in the EREB2.5 23 complementation assay since type 2 strains of EBV usually give rise to a low 24 efficiency transformation of primary B cells. It is possible that the 2 repeat type 1 25 20 EBNA-LP expressed from both the type 1 and type 2 EBNA2 expression vectors used 1 in this paper cooperates more effectively with the type 1 EBNA2 than the type 2 2 EBNA2 but there is no specific evidence for this. The EBNA-LP activity in the 3 EREB2.5 cells is further complicated by the presence of the P3HR1 truncated EBNA-4 LP, which has recently been reported to be a gain of function mutant, acquiring the 5 ability to inactivate protein phosphatase 2A (13). These additional levels of 6 complexity have not yet been explored in our study but they do not affect our 7 conclusion that there can be differential regulation of a relatively small number of cell 8 genes by type 1 and type 2 EBNA2. 9
10
The Akata cell line used for the microarray analysis and apoptosis studies in this 11
paper has an 8:14 translocation (41) similar to the BL cell lines studied previously 12 transfection and could only be performed on a small scale so it was only possible to 24 test a few EBNA2 target genes by Western blotting (Fig 1C) or RT-PCR (Fig 4B) . It 25 is noticeable that RUNX3, which is known to be required for LCL proliferation (38) 1 and was differentially expressed in the LCL experiment (Fig 1C) , was not in the list of 2 differentially regulated target genes in the Akata BL system (Fig 2) . Although 3 RUNX3 was confirmed as an EBNA2 target gene in BL cells (28), it was only 4 slightly induced in those experiments and it seems likely that differences in the 5 transcription factor content in the different cell backgrounds will affect which genes 6 are detected as EBNA2 targets, as will the different experimental procedures used. 7
However, the biochemical functions of the four genes identified in Figure 2 , namely 8
MARCKS, IL1β
ADAMDEC1 and CXCR7, are likely to be relevant to B cell 9 proliferation and survival. ADAMDEC1 and CXCR7 were also shown to be 10 differentially regulated by type 1 and type 2 EBNA2 in the LCL background (Fig 4B) . shown to be induced by EBV infection (6) although in our experiments the induced 18 level of MARCKS RNA was still very low so it is probably also regulated by another 19 EBV gene product apart from EBNA2. IL1β is a cytokine involved in lymphocyte 20 proliferation and has been reported previously to be expressed in EBV infected LCLs 21 (26). Its function normally requires that it is secreted so that it can activate via its 22 specific receptor but intracellular IL1β protein similar to that seen in our BL studies 23 has been studied previously as an inhibitor of caspase activation (42) and intracellular 24 IL-1α precursor form has been reported to function as a transcription regulator (8, 45) 25 For each condition the values were averaged and a standard error was calculated. 25
